Wonder what IP properties Regen has versus what Koos has stashed in his other businesses?
Quite the collection;
David R. Koos, 62 has served as Chairman of the Board of Directors, Chief Executive Officer, President, Secretary and Treasurer from inception to the date of this document. David R. Koos served as Chief Financial Officer since inception to July 21, 2020
Position: Company Name: Employment Dates:
Chairman, President, Chief Executive Officer, Secretary, Acting Chief Financial Officer, Principal Accounting Officer Entest Group, Inc. June 19, 2009 to November 28, 2018
Chairman, President, Chief Executive Officer, Secretary, Chief Financial Officer, Principal Accounting Officer Entest BioMedical, Inc.( a California corporation) August 22,2008 to the Present
Chairman and CEO Regen BioPharma, Inc. April 24, 2012 to January 22,2020
Acting CFO Regen BioPharma, Inc. April 24, 2012 to February 11, 2015
President Regen BioPharma, Inc. May 29, 2013 to October 9, 2013
Chairman, CEO Zander Therapeutics, Inc. February 2017 to January 22,2020
Sole Officer and Director Cell Source Research, Inc. March 24, 2003 to the Present
Chairman, President, CEO and Acting CFO Bio-Matrix Scientific Group, Inc. June 14, 2006 (Chairman) to July 31;2019 June 19, 2006 (President, CEO and Acting CFO); June 19, 2006 (Secretary) to July 31, 2019
Chairman & CEO BST Partners Inc. (A California Corporation) November 30, 2018 to the Present
Chairman & CEO BST Partners Inc. (A Wyoming Corporation) March 17, to 2017 to the Present
Chairman and Sole Officer Regen Biopharma, Inc. March 23,2021 to the Present
Chairman and Sole Officer KCL Therapeutics, Inc March 23,2021 to the Present
Chairman and Sole Officer Zander Therapeutics, Inc. March 23,2021 to the Present
